Serum group a anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic.
BACKGROUND
Vaccination during group A meningococcal epidemics is reported to decrease the number of new cases of disease. However, implementing mass vaccination is often delayed, and little information is available on whether immunity increases in a population vaccinated during an epidemic when exposure to the epidemic strain is common.


METHODS
A convenience sample of 134 previously unimmunized persons, ages 3-49 years, were immunized with a meningococcal polysaccharide vaccine. Their serum group A antibody responses were compared with those of 26 adults immunized in California with no known group A exposure.


RESULTS
Before immunization, serum anticapsular antibody concentrations were 10-fold higher in Sudanese adults and 4-fold higher in Sudanese, ages 3-17 years, than in North American adults (geometric means, 29 and 13 microg/ml, respectively, versus 3 microg/ml, P < 0.001). Seventy-five percent of the Sudanese had serum bactericidal titers that correlate with protection (> or 1/128). Nearly all Sudanese with low bactericidal titers before vaccination developed protective bactericidal antibody responses after vaccination, and the magnitude of the anticapsular antibody responses of the Sudanese was similar to that of the immunized North Americans.


CONCLUSIONS
The high titers of naturally acquired antibody in the Sudanese may reflect widespread exposure to the epidemic strain and underscore difficulties of instituting immunization before exposure occurs. Also epidemics in sub-Saharan Africans may not abate even if 75% of the population is immune to disease as long as the organism is transmitted widely among both immune and susceptible persons.
Children's Hospital Oakland Research Institute, Oakland, CA, USA.
Adil A
AA
Ismail
Shannon L
SL
Harris
Dan M
DM
Granoff
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000032:analysis* / Q000276:immunology*; D000917:Antibody Formation; D016667:Bacterial Capsules / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D004196:Disease Outbreaks; D005260:Female; D006801:Humans; D017589:Immunization Programs; D008297:Male; D008585:Meningitis, Meningococcal / Q000453:epidemiology* / Q000276:immunology* / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D013397:Sudan / Q000453:epidemiology
D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines